Hyperfine, Inc. 2025 Annual Report: Key Investor Insights

Company Overview

Hyperfine, Inc. (Nasdaq: HYPR), headquartered in Guilford, CT, is an early-stage health technology company specializing in electromedical and electrotherapeutic apparatus. The company operates with subsidiaries including Legacy Hyperfine and Liminal Sciences, Inc., and is registered as a “controlled company” under Nasdaq rules, meaning certain corporate governance protections may not apply to all shareholders.

Financial and Shareholder Information

• Market Capitalization: As of the last business day of its most recent second fiscal quarter, Hyperfine’s public float was approximately \$44.2 million.
• Shares Outstanding: As of March 13, 2026, Hyperfine had 82,902,422 shares of Class A common stock and 15,055,288 shares of Class B common stock outstanding.
• Trading Information: Class A common stock (par value \$0.0001 per share) trades under the symbol “HYPR” on the Nasdaq Stock Market LLC.
• Filing Status: The company is a non-accelerated filer, a smaller reporting company, and an emerging growth company. It is not a shell company and has complied with all reporting requirements and interactive data file submissions.
• Dual-Class Structure: Voting power is concentrated with Jonathan M. Rothberg, Ph.D., Founder of Legacy Hyperfine and Liminal, which limits other investors’ influence on key transactions, including potential changes in control.

Forward-Looking Statements & Key Risks

Hyperfine’s annual report contains numerous forward-looking statements regarding product development, expansion plans, fundraising needs, financial performance, and regulatory risks. The company warns that these statements are subject to risks, uncertainties, and assumptions, and actual results may differ materially. Notable risks include:

• History of net losses, expected to continue; profitability is uncertain.
• Potential need for additional capital to fund commercialization, R&D, clinical evidence, and new products.
• Dependence on market acceptance for products and services; ability to innovate and generate meaningful revenue remains unproven.
• Rapid technological change in health technology could render current products obsolete.
• Limited operating history makes future performance difficult to predict.
• Exposure to unfavorable global economic conditions, regulatory changes, and market volatility.
• If material weaknesses arise in internal controls over financial reporting, it could impact investor confidence and compliance with exchange listing requirements.
• Future sales of substantial amounts of Class A common stock could adversely affect share price.
• As a “controlled company,” some governance protections may not apply, increasing risks for minority shareholders.
• Competition remains intense, and the company faces risks from geopolitical conflicts, inflation, and U.S. export controls and tariffs.

Potential Price-Sensitive Factors for Shareholders

The annual report highlights several factors that may significantly impact share value:

• Need for Additional Capital: Hyperfine may seek further financing to execute commercialization, manufacturing, and R&D plans. The success and timing of future raises could affect share price, dilution, and investor sentiment.
• Continued Losses: The company expects ongoing losses, making future profitability uncertain. This could weigh heavily on investor confidence and impact market valuation.
• Regulatory and Competitive Risks: Extensive regulation and evolving technology could disrupt business plans or result in significant costs, affecting financial performance and share value.
• Controlled Company Status: Concentration of voting power and the dual-class structure may limit shareholder influence and could affect the company’s attractiveness to certain investors.
• Market Conditions: Broader economic instability, inflation, and geopolitical tensions are cited as risks that may adversely affect operations and share price.

Documents Incorporated by Reference

Certain information required in Part III of this Annual Report is incorporated by reference from the Proxy Statement for the 2026 Annual Meeting of Stockholders.

Cautionary Statement

The company emphasizes that forward-looking statements are not guarantees of future performance and are subject to numerous risks. Investors should review “Risk Factors” in Item 1A and other sections of the report for a comprehensive understanding of the risks facing Hyperfine.

Disclaimer

This article is for informational purposes only and does not constitute investment advice. Investors should conduct their own research and consult with financial advisors before making investment decisions. The information is based on the Hyperfine, Inc. 2025 Annual Report and may be subject to updates or changes. Past performance is not indicative of future results. Hyperfine, Inc. makes no commitment to update forward-looking statements except as required by law.

View Hyperfine, Inc. Historical chart here